Insider Buying: ProKidney Corp. (NASDAQ:PROK) Insider Purchases 387,393 Shares of Stock

ProKidney Corp. (NASDAQ:PROK) insider Control Empresarial De Capital purchased 387,393 shares of the stock in a transaction that occurred on Tuesday, April 22nd. The stock was bought at an average price of $0.71 per share, with a total value of $275,049.03. Following the completion of the acquisition, the insider now owns 73,842,723 shares in the company, valued at $52,428,333.33. This represents a 0.53 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Control Empresarial De Capital also recently made the following trade(s):

• On Wednesday, April 16th, Control Empresarial De Capital bought 100,000 shares of ProKidney stock. The stock was bought at an average cost of $0.75 per share, with a total value of $75,000.00.
• On Monday, April 14th, Control Empresarial De Capital bought 268,105 shares of ProKidney stock. The shares were bought at an average price of $0.73 per share, for a total transaction of $195,716.65.
• On Thursday, April 10th, Control Empresarial De Capital purchased 1,032,218 shares of ProKidney stock. The stock was bought at an average price of $0.61 per share, with a total value of $629,652.98.

ProKidney Stock Up 8.8 %

PROK opened at $0.99 on Friday. The firm’s 50 day moving average is $0.97 and its 200-day moving average is $1.49. ProKidney Corp. has a 52-week low of $0.46 and a 52-week high of $4.44. The firm has a market capitalization of $289.83 million, a P/E ratio of -1.80 and a beta of 1.52.

ProKidney (NASDAQ:PROK) last released its quarterly earnings results on Monday, March 17th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The company had revenue of $0.08 million for the quarter. Equities analysts expect that ProKidney Corp. will post -0.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of PROK. Geode Capital Management LLC increased its holdings in ProKidney by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 2,231,930 shares of the company’s stock worth $3,773,000 after purchasing an additional 27,996 shares during the last quarter. Bleichroeder LP grew its position in shares of ProKidney by 8.4% during the fourth quarter. Bleichroeder LP now owns 2,000,000 shares of the company’s stock worth $3,380,000 after buying an additional 155,000 shares in the last quarter. State Street Corp increased its stake in shares of ProKidney by 16.2% in the third quarter. State Street Corp now owns 1,428,318 shares of the company’s stock worth $2,742,000 after buying an additional 198,836 shares during the last quarter. Northern Trust Corp raised its holdings in ProKidney by 7.4% in the fourth quarter. Northern Trust Corp now owns 890,907 shares of the company’s stock valued at $1,506,000 after acquiring an additional 61,206 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its holdings in ProKidney by 48.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 844,277 shares of the company’s stock valued at $740,000 after acquiring an additional 275,630 shares in the last quarter. Hedge funds and other institutional investors own 51.59% of the company’s stock.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.